Leveraging Physiologically Based Modelling to Provide Insights on the Absorption of Paliperidone Extended-Release Formulation under Fed and Fasting Conditions

• Main Authors: Saima Subhani (Author), Viera Lukacova (Author), Chaejin Kim (Author), Leyanis Rodriguez-Vera (Author), Paula Muniz (Author), Monica Rodriguez (Author), Rodrigo Cristofoletti (Author), Sandra Van Os (Author), Elena Suarez (Author), Stephan Schmidt (Author), Valvanera Vozmediano (Author)
• Format: Book
• Published: MDPI AG, 2023-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Paliperidone was approved by the US FDA in 2006 as an extended-release (ER) tablet (Invega^®) for the once-daily treatment of schizophrenia. This osmotic-controlled release oral delivery system (OROS) offers advantages, such as the prevention of plasma concentration fluctuation...